192 related articles for article (PubMed ID: 31045757)
21. Lung function outcomes in the INPULSIS
Brown KK; Flaherty KR; Cottin V; Raghu G; Inoue Y; Azuma A; Huggins JT; Richeldi L; Stowasser S; Stansen W; Schlenker-Herceg R; Maher TM; Wells AU
Respir Med; 2019 Jan; 146():42-48. PubMed ID: 30665517
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia.
Strand MJ; Sprunger D; Cosgrove GP; Fernandez-Perez ER; Frankel SK; Huie TJ; Olson AL; Solomon J; Brown KK; Swigris JJ
Chest; 2014 Sep; 146(3):775-785. PubMed ID: 24700149
[TBL] [Abstract][Full Text] [Related]
23. Newly defined acute exacerbation of idiopathic pulmonary fibrosis with surgically-proven usual interstitial pneumonia: risk factors and outcome.
Okuda R; Hagiwara E; Katano T; Ikeda S; Sekine A; Kitamura H; Baba T; Okudela K; Ohashi K; Ogura T
Sarcoidosis Vasc Diffuse Lung Dis; 2019; 36(1):39-46. PubMed ID: 32476935
[TBL] [Abstract][Full Text] [Related]
24. Gastroesophageal reflux disease and patterns of reflux in patients with idiopathic pulmonary fibrosis using hypopharyngeal multichannel intraluminal impedance.
Hoppo T; Komatsu Y; Jobe BA
Dis Esophagus; 2014 Aug; 27(6):530-7. PubMed ID: 23107023
[TBL] [Abstract][Full Text] [Related]
25. Autoantibody status is not associated with change in lung function or survival in patients with idiopathic pulmonary fibrosis.
Goobie GC; Ford-Sahibzada CA; Fritzler MJ; Johannson KA; Fell CD
Respir Med; 2019 Jul; 153():85-90. PubMed ID: 31176275
[TBL] [Abstract][Full Text] [Related]
26. Combined pulmonary fibrosis and emphysema: a retrospective analysis of clinical characteristics, treatment and prognosis.
Zhang L; Zhang C; Dong F; Song Q; Chi F; Liu L; Wang Y; Che C
BMC Pulm Med; 2016 Nov; 16(1):137. PubMed ID: 27809901
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness and Safety of Chinese Medicine for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Wu Q; Zhou Y; Feng FC; Zhou XM
Chin J Integr Med; 2019 Oct; 25(10):778-784. PubMed ID: 29335860
[TBL] [Abstract][Full Text] [Related]
28. A score without diffusion capacity of the lung for carbon monoxide for estimating survival in idiopathic pulmonary fibrosis.
Fukuda CY; Soares MR; de Castro Pereira CA
Medicine (Baltimore); 2020 Jun; 99(25):e20739. PubMed ID: 32569216
[TBL] [Abstract][Full Text] [Related]
29. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.
Vietri L; Cameli P; Perruzza M; Cekorja B; Bergantini L; d'Alessandro M; Refini RM; Pieroni M; Fossi A; Bennett D; Spalletti M; Mazzei MA; Sestini P; Rottoli P; Bargagli E
Ther Adv Respir Dis; 2020; 14():1753466620906326. PubMed ID: 32066332
[TBL] [Abstract][Full Text] [Related]
30. Composite Physiologic Index, Percent Forced Vital Capacity and Percent Diffusing Capacity for Carbon Monoxide Could Be Predictors of Pirfenidone Tolerability in Patients with Idiopathic Pulmonary Fibrosis.
Konishi S; Arita M; Ito I; Tachibana H; Takaiwa T; Fukuda Y; Watanabe N; Tsubouchi K; Masuda G; Tanaka M; Kourogi Y; Kunimasa K; Nishiyama A; Iwasaku M; Ito A; Tokioka F; Yoshioka H; Hashimoto T; Ishida T
Intern Med; 2015; 54(22):2835-41. PubMed ID: 26567995
[TBL] [Abstract][Full Text] [Related]
31. Risk factors for acute exacerbation of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Qiu M; Chen Y; Ye Q
Clin Respir J; 2018 Mar; 12(3):1084-1092. PubMed ID: 28332341
[TBL] [Abstract][Full Text] [Related]
32. Quantitative CT-derived vessel metrics in idiopathic pulmonary fibrosis: A structure-function study.
Jacob J; Pienn M; Payer C; Urschler M; Kokosi M; Devaraj A; Wells AU; Olschewski H
Respirology; 2019 May; 24(5):445-452. PubMed ID: 30786325
[TBL] [Abstract][Full Text] [Related]
33. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.
Zappala CJ; Latsi PI; Nicholson AG; Colby TV; Cramer D; Renzoni EA; Hansell DM; du Bois RM; Wells AU
Eur Respir J; 2010 Apr; 35(4):830-6. PubMed ID: 19840957
[TBL] [Abstract][Full Text] [Related]
34. Patients With Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening: A Large Cohort Analysis.
Moua T; Westerly BD; Dulohery MM; Daniels CE; Ryu JH; Lim KG
Chest; 2016 May; 149(5):1205-14. PubMed ID: 26836940
[TBL] [Abstract][Full Text] [Related]
35. Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study.
Lee EG; Lee TH; Hong Y; Ryoo J; Heo JW; Gil BM; Kang HS; Kwon SS; Kim YH
PLoS One; 2021; 16(12):e0261684. PubMed ID: 34941933
[TBL] [Abstract][Full Text] [Related]
36. The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis.
Kim GHJ; Goldin JG; Hayes W; Oh A; Soule B; Du S
Ther Adv Respir Dis; 2021; 15():17534666211004238. PubMed ID: 33781141
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic Human Mesenchymal Stem Cells in Patients With Idiopathic Pulmonary Fibrosis via Intravenous Delivery (AETHER): A Phase I Safety Clinical Trial.
Glassberg MK; Minkiewicz J; Toonkel RL; Simonet ES; Rubio GA; DiFede D; Shafazand S; Khan A; Pujol MV; LaRussa VF; Lancaster LH; Rosen GD; Fishman J; Mageto YN; Mendizabal A; Hare JM
Chest; 2017 May; 151(5):971-981. PubMed ID: 27890713
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis.
Homma S; Azuma A; Taniguchi H; Ogura T; Mochiduki Y; Sugiyama Y; Nakata K; Yoshimura K; Takeuchi M; Kudoh S;
Respirology; 2012 Apr; 17(3):467-77. PubMed ID: 22257422
[TBL] [Abstract][Full Text] [Related]
39. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
40. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
Jo HE; Glaspole I; Grainge C; Goh N; Hopkins PM; Moodley Y; Reynolds PN; Chapman S; Walters EH; Zappala C; Allan H; Keir GJ; Hayen A; Cooper WA; Mahar AM; Ellis S; Macansh S; Corte TJ
Eur Respir J; 2017 Feb; 49(2):. PubMed ID: 28232409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
